Pick the paper for the question
These are the papers and FDA pages linked in our recovery guides. The notes explain what each one helps with. A review gathers earlier work; an experiment reports what happened in a particular setting.
Keep an eye on what was tested, in whom and with what result. Those details matter more than a promising title.
The human evidence and its limits
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing — 2025. An overview of BPC-157 research, including the very limited human evidence. It's a review, rather than a new test of recovery.
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — 2026. A wider view of the ingredients and the shortage of rigorous human safety data. It isn't a GLOW or KLOW combination trial.
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study — Alternative Therapies in Health and Medicine, 2025. Two adults who had received intravenous BPC-157 before, with no adverse events reported in that observation. It didn't test injury healing, establish safety for first-time patients or rule out uncommon harms.
Animal and laboratory findings
Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth — 2003. Healing measures in rats with cut tendons, alongside laboratory work on tendon cells. These aren't human recovery results.
Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation — 2017. Laboratory and animal research on blood-vessel growth. It explores how an effect might happen.
GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration — 2015. A review of laboratory and skin research, including topical preparations applied to the skin. It isn't a test of an injected blend.
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation — 2008. Work in laboratory cells and mice with induced bowel inflammation. It doesn't establish a benefit for human joints.
FDA assessments and status
FDA's TB-500 assessment — July 2026 meeting materials. Separates the fragment from full thymosin beta-4 and reports no published human TB-500 studies.
FDA's BPC-157 assessment — July 2026 meeting materials. Most certificates FDA reviewed for the free-base form had purity results without impurity limits or test results. That finding concerns this form, not every BPC-157 product. A purity figure doesn't cover every safety question.
FDA's safety-risk page — current as of April 22, 2026. Lists withdrawn nominations with safety concerns still attached. Withdrawal isn't clearance for compounding.
FDA's 503A category list — updated May 14, 2026. Treats non-injectable GHK-Cu separately from injections. Category 1 isn't drug approval.